文献速递胸部肿瘤头颈与中枢神经肿瘤

EGFR突变肺癌伴中枢神经系统转移的基因组图谱识别

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.
PubMed 文献 · Ann Oncol · 2025-06-16

该研究分析接受一线奥希替尼治疗的EGFR突变非小细胞肺癌患者(颅外NGS n=262,颅内NGS n=81,配对14例)的临床基因组特征,发现53%发生中枢神经系统转移(36%初诊时即存在,16%治疗中获得),中枢神经系统转移与颅外CARD11扩增频率较高及MDM2扩增频率较低相关,治疗中获得中枢神经系统转移者总生存更差。

要点

  • 一线奥希替尼治疗的262例患者中53%发生中枢神经系统转移,其中36%为初诊时即存在,16%为治疗中获得。
  • 中枢神经系统转移者颅外CARD11扩增频率较高(14% vs 3%,P=0.031),MDM2扩增频率较低(1% vs 13%,P=0.008)。
  • 治疗中获得中枢神经系统转移者总生存较从未发生者差(HR=3.67,95%CI 2.41-5.59)。

核心结论

  • 携带非典型EGFR突变或奥希替尼治疗中获得中枢神经系统转移的患者结局更差。
  • 颅内与颅外肿瘤比较NGS提示中枢神经系统播散由单基因变异之外的机制驱动。

研究设计与样本

  • 分析接受一线奥希替尼治疗的EGFR突变非小细胞肺癌患者的临床基因组特征,颅外NGS n=262,颅内NGS n=81,配对颅内外NGS 14例。
  • 时间-事件分析从转移诊断时开始,治疗中止时间(TTD)从治疗开始时计算。

主要发现

  • 262例接受一线奥希替尼治疗的患者中53%发生中枢神经系统转移(36%初诊时即存在,16%治疗中获得)。
  • 脑转移和软脑膜转移的1年累积发生率分别为39%和2%,3年分别为49%和6%,5年分别为54%和12%。
  • 中枢神经系统转移与颅外NGS标本中CARD11扩增频率较高相关(14% vs 3%,P=0.031),与MDM2扩增频率较低相关(1% vs 13%,P=0.008),其余基因组图谱相似。
  • 与从未发生中枢神经系统转移者相比,治疗中获得中枢神经系统转移者总生存更差(HR=3.67,95%CI 2.41-5.59),初诊时即存在者次之(HR=1.61,95%CI 1.15-2.26)(P<0.001)。
  • 多变量Cox回归中,非典型EGFR突变与较短总生存相关;细胞周期通路变异在脑转移样本中较软脑膜转移样本更常见(93% vs 47%,P=0.003,q=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the intracranial efficacy of osimertinib, central nervous system (CNS) metastases remain a major cause of morbidity and mortality in EGFR-mutant non-small-cell lung cancer (NSCLC). The genomic drivers of CNS dissemination are poorly understood. PATIENTS AND METHODS: We analyzed the clinicogenomic features of patients with EGFR-mutant NSCLC receiving first-line osimertinib with extracranial next generation sequencing (NGS) (n = 262) and individuals with intracranial NGS (n = 81). Paired extra- and intracranial NGS was available for 14 patients. Time-to-event analyses were conducted from time of metastatic diagnosis, except for time-to-treatment discontinuation (TTD), which began at treatment initiation. RESULTS: Among 262 patients receiving first-line osimertinib, 53% developed CNS metastases (36% de novo, 16% acquired on treatment). The cumulative incidence of brain (BrM) and leptomeningeal metastases (LM) was 39% and 2% at 1 year, 49% and 6% at 3 years, and 54% and 12% at 5 years, respectively. CNS metastases correlated with a higher frequency of CARD11 amplifications (14% versus 3%, P = 0.031) and a lower frequency of MDM2 amplifications (1% versus 13%, P = 0.008) in extracranial NGS specimens, with otherwise similar genomic profiles. Patients who developed CNS metastases on treatment had worse overall survival (OS) [hazard ratio (HR) = 3.67, 95% confidence interval (CI) 2.41 to 5.59], followed by those with de novo (HR = 1.61, 95% CI 1.15 to 2.26), compared with those who never developed CNS metastases (P < 0.001). In multivariable Cox regression, atypical EGFR mutations were associated with shorter OS. Cell cycle pathway alterations were more frequent in BrM than LM samples (93% versus 47%, P = 0.003, q = 0.03). No other significant genomic differences were found between BrM and LM, or between paired CNS and systemic samples. CONCLUSIONS: Patients with atypical EGFR mutations or acquired CNS metastases on osimertinib have worse outcomes. Comparative NGS profiling of intra- and extracranial tumors suggest that CNS dissemination is driven by mechanisms beyond single-gene alterations.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wilcox JA, Jeng MY, Tischfield S, et al. Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases. Ann Oncol. 2025. PMID: 40532851. doi:10.1016/j.annonc.2025.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。